Keir ST - Search Results

1

Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program.

Gorlick R, Kolb EA, Houghton PJ, Morton CL, Phelps D, Schaiquevich P, Stewart C, Keir ST, Lock R, Carol H, Reynolds CP, Maris JM, Wu J, Smith MA. Gorlick R, et al. Among authors: keir st. Pediatr Blood Cancer. 2009 Oct;53(4):594-8. doi: 10.1002/pbc.21989. Pediatr Blood Cancer. 2009. PMID: 19554571 Free PMC article.

2

Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts.

Friedman HS, Houghton PJ, Schold SC, Keir S, Bigner DD. Friedman HS, et al. Cancer Chemother Pharmacol. 1994;34(2):171-4. doi: 10.1007/BF00685936. Cancer Chemother Pharmacol. 1994. PMID: 8194169

3

Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.

Hare CB, Elion GB, Houghton PJ, Houghton JA, Keir S, Marcelli SL, Bigner DD, Friedman HS. Hare CB, et al. Cancer Chemother Pharmacol. 1997;39(3):187-91. doi: 10.1007/s002800050558. Cancer Chemother Pharmacol. 1997. PMID: 8996518

4

Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts.

Castellino RC, Elion GB, Keir ST, Houghton PJ, Johnson SP, Bigner DD, Friedman HS. Castellino RC, et al. Among authors: keir st. Cancer Chemother Pharmacol. 2000;45(4):345-9. doi: 10.1007/s002800050050. Cancer Chemother Pharmacol. 2000. PMID: 10755324

5

Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice.

Friedman HS, Keir ST, Houghton PJ, Lawless AA, Bigner DD, Waters SJ. Friedman HS, et al. Among authors: keir st. Cancer Chemother Pharmacol. 2001 Nov;48(5):413-6. doi: 10.1007/s002800100358. Cancer Chemother Pharmacol. 2001. PMID: 11761460

6

O6-benzylguanine-mediated enhancement of chemotherapy.

Friedman HS, Keir S, Pegg AE, Houghton PJ, Colvin OM, Moschel RC, Bigner DD, Dolan ME. Friedman HS, et al. Mol Cancer Ther. 2002 Sep;1(11):943-8. Mol Cancer Ther. 2002. PMID: 12481416

7

The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.

Friedman HS, Keir ST, Houghton PJ. Friedman HS, et al. Among authors: keir st. Cancer. 2003 May 1;97(9 Suppl):2359-62. doi: 10.1002/cncr.11305. Cancer. 2003. PMID: 12712457 Free article. Review.

8

The pediatric preclinical testing program: description of models and early testing results.

Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Tajbakhsh M, Reynolds CP, Maris JM, Courtright J, Keir ST, Friedman HS, Stopford C, Zeidner J, Wu J, Liu T, Billups CA, Khan J, Ansher S, Zhang J, Smith MA. Houghton PJ, et al. Among authors: keir st. Pediatr Blood Cancer. 2007 Dec;49(7):928-40. doi: 10.1002/pbc.21078. Pediatr Blood Cancer. 2007. PMID: 17066459

9

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.

Houghton PJ, Morton CL, Kolb EA, Lock R, Carol H, Reynolds CP, Keshelava N, Maris JM, Keir ST, Wu J, Smith MA. Houghton PJ, et al. Among authors: keir st. Pediatr Blood Cancer. 2008 Jan;50(1):37-45. doi: 10.1002/pbc.21214. Pediatr Blood Cancer. 2008. PMID: 17420992

10

Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.

Maris JM, Courtright J, Houghton PJ, Morton CL, Gorlick R, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA. Maris JM, et al. Among authors: keir st. Pediatr Blood Cancer. 2008 Mar;50(3):581-7. doi: 10.1002/pbc.21232. Pediatr Blood Cancer. 2008. PMID: 17457854

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

154 results

Search Page

Filters